Articles

Evaluation of real-world reports will help with the early clinical assessment of interstitial lung disease potentially associated with CDK4/6 inhibitors. Read More ›

An electronic home-based multidimensional cancer survivorship program did not clearly affect outcomes in women with breast cancer, although a positive impact was revealed in interviews. Read More ›

Pooled analyses of overall survival shows the addition of CDK inhibitors to fulvestrant confers a consistent survival benefit in patients with breast cancer. Read More ›

As mutation-associated targeted therapies are identified, it is critical to address genetic testing disparities. Read More ›

CDK4/6 inhibitors have similar efficacy; therefore, clinicians should consider toxicity when selecting an optimal therapeutic approach. Read More ›

Nationwide Children’s Hospital in Columbus, OH, is one of the largest pediatric hospitals in the United States and is currently ranked as one of the top 10 children’s hospitals in the country by US News & World Report’s 2020-2021 “Best Children’s Hospitals Honor Roll” list. Read More ›

Gastrointestinal (GI) malignancies account for 26% of the global cancer incidence and 35% of all cancer-related deaths. Read More ›

The addition of the PI3K inhibitor copanlisib (Aliopa) to rituximab (Rituxan) reduced the risk for disease progression or death by 48% compared with rituximab alone in patients with relapsed indolent non-Hodgkin lymphoma (NHL) in the phase 3 CHRONOS-3 clinical trial. Read More ›